Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2016 2
2018 2
2019 2
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
Akaza H, Procopio G, Pripatnanont C, Facchini G, Fava S, Wheatley D, Leung KC, Butt M, Silva A, Castillo L, Karavasilis V, Ӧzatılgan A, Hitier S, Ecstein-Fraisse EB, Ӧzgüroḡlu M. Akaza H, et al. Among authors: ecstein fraisse eb. J Glob Oncol. 2018 Sep;4:1-12. doi: 10.1200/JGO.18.00009. J Glob Oncol. 2018. PMID: 30260754 Free PMC article.
Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry.
Malik Z, Di Lorenzo G, Pichler A, De Giorgi U, Hitier S, Ecstein-Fraisse E, Ozatilgan A, Carles J. Malik Z, et al. Among authors: ecstein fraisse e. Cancers (Basel). 2020 Apr 17;12(4):995. doi: 10.3390/cancers12040995. Cancers (Basel). 2020. PMID: 32316580 Free PMC article.
Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme.
Malik Z, Heidenreich A, Bracarda S, Ardavanis A, Parente P, Scholz HJ, Ozatilgan A, Ecstein-Fraisse E, Hitier S, Di Lorenzo G. Malik Z, et al. Among authors: ecstein fraisse e. Oncotarget. 2019 Jun 25;10(41):4161-4168. doi: 10.18632/oncotarget.27031. eCollection 2019 Jun 25. Oncotarget. 2019. PMID: 31289614 Free PMC article.
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D. Heidenreich A, et al. Among authors: ecstein fraisse e. Eur Urol. 2013 Jun;63(6):977-82. doi: 10.1016/j.eururo.2012.08.058. Epub 2012 Sep 3. Eur Urol. 2013. PMID: 23116658
Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M. Kosaka T, et al. Among authors: ecstein fraisse e. Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051. Jpn J Clin Oncol. 2019. PMID: 31329922 Free PMC article. Clinical Trial.